Abstract
17α-Hydroxylase/17,20-lyase is a target in the treatment of hormone-dependent prostate cancer. Here we report the results of a study into a range of alkanesulfonate derivatives of 4-hydroxybenzylimidazole which show the compounds to be good inhibitors with 5 [IC50=1.11μM (17α-OHase) and IC50=1.28μM (lyase)] being the most potent but weaker than ketoconazole.
Original language | English |
---|---|
Pages (from-to) | 1000-1009 |
Number of pages | 10 |
Journal | Letters in Drug Design & Discovery |
Volume | 11 |
Issue number | 8 |
Publication status | Published - 1 Oct 2014 |
Externally published | Yes |
Keywords
- 17α-OHase
- 17α-hydroxylase/17
- 20-lyase
- Azole
- Inhibitors Lyase